P2Y purinoceptor 12 is a protein that in humans is encoded by the P2RY14 gene.
P2Y12 belongs to the family of G-protein coupled receptors, with receptor subtypes with different pharmacological selectivity for various adenosine and uridine nucleotides.
P2Y purinergic receptor for UDP-glucose and other UDP-sugars coupled to G-proteins.
P2Y receptors are a family of seven transmembrane spanning G protein-coupled receptors that are activated by nucleotides and nucleotide-sugars.
The P2Y12R is activated by nucleotide sugars.
The thienopyridine antithrombotic drugs Clopidogrel, ticagrelor, and Prasugrel require enzymatic pre-activation in vivo and react irreversibly with the P2Y12 receptor.
The P2y12 pathway is a therapeutic target for the inhibition of platelet activation with clopidogral treatment.
P2Y12 inhibitors are a class of antiplatelet drugs that block the P2Y12 receptor on platelets, thereby inhibiting adenosine diphosphate (ADP)-mediated platelet activation and aggregation.
These agents are central to the prevention of arterial thrombosis, especially in patients with acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI).
The most commonly used oral P2Y12 inhibitors are clopidogrel, prasugrel, and ticagrelor.
Clopidogrel and prasugrel are thienopyridines and act as irreversible inhibitors, requiring metabolic activation (clopidogrel via CYP2C19, prasugrel via other CYP enzymes).
Ticagrelor is a cyclopentyltriazolopyrimidine and acts as a reversible, direct-acting inhibitor, not requiring metabolic activation.
Cangrelor is an intravenous, reversible P2Y12 inhibitor used in specific settings.
By blocking the P2Y12 receptor, these drugs prevent ADP from activating platelets, reducing the risk of thrombus formation.
This mechanism is complementary to aspirin, which inhibits thromboxane A2–mediated platelet activation.
Dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) is standard for ACS and post-stenting to reduce major adverse cardiovascular events, though it increases bleeding risk.
Any of the above agents are usually combined with low dose of aspirin as dual antiplatelet therapy in patients with acute coronary syndromes or who have undergone coronary stent implantation to decrease the risk of platelet-mediated thrombotic cardiovascular events.
Current guidelines for dual antiplatelet therapy consisted of aspirin and the more potent platelet inhibitors ticagrelor and prasurgrel over clopidogrel because these drugs are more effective for the prevention of thrombotic events, but have a higher risk of bleeding.